A 2026 Centers for Disease Control and Prevention (CDC) clinician summary recommends initiating oral or enterically administered oseltamivir as soon as possible in all hospitalized patients with suspected or confirmed influenza, without awaiting laboratory confirmation; observational evidence indicates that benefit is greatest with early treatment but may persist when treatment is initiated more than 48 hours after symptom onset. At the time, no sufficiently powered, randomized, placebo-controlled trials of neuraminidase inhibitor monotherapy had been completed in hospitalized patients; however, observational studies have associated treatment with shorter hospitalization and reduced risks of intensive care unit (ICU) transfer, invasive mechanical ventilation, or death, although some studies have not demonstrated a mortality reduction. Standard-dose oseltamivir achieves therapeutic concentrations in critically ill adults, including limited data involving administration through gastric tubes and use during continuous renal replacement therapy or extracorporeal membrane oxygenation, whereas available evidence does not indicate additional clinical benefit from higher dosing. The optimal treatment duration in severe or complicated influenza remains uncertain; longer treatment may be considered for patients who remain severely ill after 5 days or have prolonged lower respiratory tract viral replication, with decisions guided by clinical judgment and, when appropriate, lower respiratory tract RT-PCR testing. Inhaled zanamivir, intravenous peramivir, and oral baloxavir are not routinely recommended for hospitalized patients because clinical-benefit data are insufficient, and adding baloxavir to a neuraminidase inhibitor did not improve time to clinical improvement in one randomized trial. [1]
The 2024 World Health Organization (WHO) clinical practice guideline conditionally recommends oseltamivir for patients with suspected or confirmed severe influenza, including infections caused by novel influenza A viruses associated with high mortality or an unknown risk of severe disease, based on very-low-quality evidence; treatment should be initiated as early as possible and within 2 days of symptom onset. Evidence was derived from 2 randomized controlled trials involving 104 patients with severe influenza and indicated that oseltamivir may reduce hospitalization duration by 1.63 days versus standard care or placebo (95% confidence interval [CI] 0.45 to 2.81 days fewer; low-certainty evidence), whereas its effects on seasonal influenza mortality (risk ratio [RR] 0.53; 95% CI 0.07 to 4.24) and intensive care unit admission were very uncertain. The recommended adult dosage is 75 mg orally twice daily for 5 days, with renal dose adjustment as indicated; longer treatment may be considered for severe or zoonotic influenza and in immunocompromised patients. Oseltamivir may be administered enterically through an orogastric or nasogastric tube in intubated patients and is well absorbed by this route, but the guideline identifies malabsorption, gastric stasis, ileus, and gastrointestinal bleeding as contraindications to enteric administration. [2]
The October 2026 UK Health Security Agency (UKHSA) guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza continues to recommend oseltamivir as first-line treatment for patients with severe influenza, including those who are critically ill. The guidance emphasizes that antiviral treatment provides the greatest benefit when initiated within 48 hours of symptom onset, although treatment initiated up to 5 days after symptom onset may still be beneficial. Notably, the guidance acknowledges preliminary findings from the 2026 REMAP-CAP trial, which demonstrated no mortality benefit and reported higher mortality with oseltamivir compared with no antiviral treatment in critically ill patients, leading to early termination of the oseltamivir treatment arms. However, the guidance notes that treatment was initiated a median of 5 days after symptom onset, limiting generalizability to patients treated earlier, and identifies additional evidence gaps involving cause-specific mortality, influenza subtypes, and viral load. When oseltamivir cannot be administered promptly or is unsuitable, alternative treatments, including baloxavir or zanamivir, may be considered under specialist guidance, although supporting clinical evidence remains limited. The guidance states that treatment recommendations will continue to be reviewed as additional REMAP-CAP data and results from ongoing randomized trials, including the RECOVERY trial, which continues to enroll critically ill patients for randomization to oseltamivir monotherapy, become available. [3]
Interestingly, the October 2026 Australian Living Evidence Collaboration guideline provides a strong recommendation against oseltamivir in critically ill adults aged >12 years with confirmed or suspected influenza, regardless of symptom duration, including those who are immunocompromised, pregnant, experiencing shock, or have bacterial coinfection. The guideline also recommends discontinuing oseltamivir in patients who develop critical illness during treatment. These recommendations are based on the REMAP-CAP trial, which demonstrated no clinical benefit and suggested an increased risk of mortality with oseltamivir compared with standard care alone (moderate-certainty evidence). For children aged ≤12 years with influenza-associated respiratory failure, the guideline conditionally recommends against oseltamivir, citing a lack of direct pediatric evidence and potential harm suggested by adult data (low-certainty evidence). However, oseltamivir may be considered on a case-by-case basis for critically ill children with nonrespiratory manifestations, such as encephalopathy or myocarditis, following specialist consultation. [4]
A 2025 narrative review evaluating antiviral therapy for critically ill patients with influenza reported that no randomized controlled trials have specifically assessed oseltamivir in this population; however, six prospective or retrospective observational studies consistently associated early oseltamivir administration with improved survival or reduced mortality. International guidelines recommend initiating oseltamivir as soon as possible in hospitalized patients with severe influenza, including when illness has been present for more than 48 hours, although the strength and quality of supporting evidence vary. The usual recommended regimen is 75 mg twice daily for 5 days, adjusted for renal impairment; extending treatment to 10 days may be reasonable in immunocompromised patients or those with persistent symptoms and viral shedding at day 5, whereas higher-dose oseltamivir (150 mg twice daily) has not demonstrated faster viral-load reduction or clinical superiority. The review also noted limited and variable pharmacokinetic data in critically ill patients and emphasized that persistent viral replication, particularly among immunocompromised patients, may promote oseltamivir resistance and warrant resistance testing and consideration of an alternative antiviral. [5]
A 2024 network meta-analysis evaluated 8 randomized controlled trials involving 1,424 hospitalized patients with severe suspected or laboratory-confirmed influenza, with 6 trials included in the network meta-analysis. Compared with placebo or standard care, oseltamivir might reduce hospitalization duration (3.37 vs 5.00 days; mean difference [MD] −1.63 days; 95% CI −2.81 to −0.45; low-certainty evidence) but demonstrated little or no difference in time to symptom alleviation (MD 0.34 days; 95% CI −0.86 to 1.54; low-certainty evidence). The effect of oseltamivir on mortality was very uncertain (risk ratio [RR] 0.53; 95% CI 0.07 to 4.24; very-low-certainty evidence), and uncertainty remained regarding ICU admission, progression to mechanical ventilation, and other clinically important outcomes. The included trials did not report treatment timing relative to symptom onset, precluding evaluation of early versus delayed oseltamivir initiation. [6]
A 2014 individual-participant-data meta-analysis of 78 observational studies evaluated neuraminidase inhibitor treatment and mortality among 29,234 patients hospitalized with pandemic influenza A(H1N1)pdm09, including 6,828 patients admitted to critical care; oral oseltamivir accounted for 92% of reported neuraminidase inhibitor use. Among critically ill adults, treatment at any time was associated with lower mortality versus no treatment (adjusted odds ratio [OR] 0.72; 95% CI 0.56 to 0.94), while treatment initiated within 2 days of symptom onset was associated with lower mortality versus later treatment (adjusted OR 0.62; 95% CI 0.49 to 0.77) and no treatment (adjusted OR 0.31; 95% CI 0.20 to 0.47). Treatment initiated more than 2 days after symptom onset was also associated with lower mortality versus no treatment in critically ill adults (adjusted OR 0.65; 95% CI 0.46 to 0.93); corresponding associations were not statistically significant in critically ill children. The authors advocated early neuraminidase inhibitor treatment in adults hospitalized with suspected or confirmed influenza but acknowledged the observational design, inability to adjust specifically for disease severity, potential residual confounding, and missing treatment-exposure data. [7]